REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pathwork Diagnostics, Inc., a pioneer in creating genomics-based diagnostics in oncology utilizing their proprietary informatics platform, today announced that Deborah Neff, Pathwork’s Chief Executive Officer, will present at the Lazard Capital Markets 8th Annual Healthcare Conference in New York City on Tuesday, November 15th at 3:30 p.m. ET. Ms. Neff will discuss the company’s platform technology and commercialized products, including the Pathwork® Tissue of Origin Test, which aids pathologists and oncologists in the diagnosis of challenging cancer cases.
About Pathwork Diagnostics
Pathwork Diagnostics created its proprietary informatics platform to develop high-value, medically important diagnostics aimed at helping guide cancer care. Pathwork has commercialized its Pathwork Tissue of Origin product line, and has a robust pipeline and growing portfolio of pharmaceutical partners. Pathwork is privately held and based in Redwood City, CA. For more information call toll-free (877) 808-0006 or visit www.pathworkdx.com.
About the Pathwork Tissue of Origin Test
The company’s Pathwork Tissue of Origin Test is the only FDA-cleared, Medicare-covered molecular diagnostic test for identifying tissue of origin. It uses a tumor's own genomic information to help pathologists and oncologists in the diagnosis of challenging cancer cases such as those that are metastatic or that have a complex clinical history.
The Pathwork Tissue of Origin Test, available through the Pathwork Diagnostics Laboratory, measures gene expression levels of 2,000 genes and uses proprietary algorithms to compare the tumor’s gene expression pattern to that of 15 tumor types, representing 58 morphologies and 90% of all solid tumors. The test provides objective genomic information to help the physician diagnose what type of cancer the patient has. An accurate diagnosis allows oncologists to match therapy to the cancer.
The Pathwork Tissue of Origin Test has been extensively evaluated in multiple independent studies involving more than 1,100 patient specimens, including large validation studies published in the Journal of Clinical Oncology and the Journal of Molecular Diagnostics.
A retrospective study of 111 cases from 66 academic and community oncology practices illustrates the use of the test in management of cancer patients. Over two thirds of the cases reviewed showed cancer management changed after the Pathwork Tissue of Origin Test result was received. The majority of the oncologists identified the Tissue of Origin Test results as influencing the decision to make a change in therapy.